GLP-1 Agonist Phase III

LY-343794

Also known as: Orforglipron, LY3502970

An oral non-peptide GLP-1 agonist delivering injectable-level weight loss in a simple daily pill — the future of accessible weight management therapy.

Popularity B+
Class Oral Non-Peptide GLP-1 Receptor Agonist
Half-Life ~29-49 hours
Form Oral tablet/capsule
View Vendors → Jump to Dosing ↓
LY-343794 C30H36ClF3N4O3
Research-Backed User Reports Sourced Updated Mar 2026
// Overview

What is LY-343794?

LY-343794, now known as Orforglipron, is a first-in-class oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (Rybelsus), which is still a peptide requiring special formulation, orforglipron is a small molecule that can be taken as a simple daily pill without the restrictions of peptide-based oral delivery.

In Phase 2 trials, orforglipron produced up to 14.7% body weight loss at the highest dose over 36 weeks — comparable to injectable semaglutide — making it the most promising oral-only weight loss drug in development. The convenience of a daily pill without injection or fasting requirements could dramatically expand the patient population willing to use GLP-1 therapy.

As a non-peptide molecule, orforglipron is cheaper to manufacture, more stable (no refrigeration needed), and easier to administer than injectable GLP-1 agonists. It represents the potential future of GLP-1 therapy: equivalent efficacy in a simple pill.

Looking for the best vendor deals?

Compare prices across 10+ peptide and anabolic vendors. Find the best quality at the lowest price.

Compare Vendors
// How It Works

How LY-343794 Works

Orforglipron is a small molecule that activates the GLP-1 receptor through a non-peptide mechanism:

  1. GLP-1 receptor agonism — Binds to and activates the GLP-1 receptor in a similar manner to native GLP-1, despite being a completely different molecular class (small molecule vs peptide).
  2. Appetite suppression — Activates GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety, similar to semaglutide.
  3. Gastric emptying delay — Slows stomach emptying to prolong feelings of fullness after meals.
  4. Insulin regulation — Enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release.
  5. Non-peptide advantage — As a small molecule, orforglipron is not degraded by stomach acid or proteases, allowing simple oral dosing without special formulation or fasting requirements.
// Dosage Protocols

Dosage Information (User-Reported)

Disclaimer: Dosage information is compiled from user reports and published research. This is not medical advice. Consult a healthcare professional before use.
Level Dose Frequency Duration
Titration Start 3 mg Once daily (oral) 2 weeks
Titration Step 2 6-12 mg Once daily 2 weeks
Therapeutic Low 24 mg Once daily Ongoing
Therapeutic Mid 36 mg Once daily Ongoing
Therapeutic High 45 mg Once daily Ongoing

What to Expect

Week 1-4

Appetite begins decreasing. GI side effects (nausea) during titration, similar to injectable GLP-1s. Convenience of daily pill appreciated.

Week 5-12

Significant appetite suppression at therapeutic doses. Steady weight loss of 1-2 lbs/week. Nausea typically resolving.

Month 3-6

Substantial weight loss (10-15%). Body composition improving. Metabolic markers normalizing.

Month 6-9

Approaching peak weight loss. Results comparable to injectable semaglutide without the injections.

Common Stacks

BPC-157

GI Protection

Manages nausea and gastric effects from GLP-1 receptor activation

L-Carnitine

Fat Metabolism

Enhances fatty acid oxidation during accelerated weight loss

Protein Supplementation

Lean Mass Preservation

Critical during rapid weight loss to maintain muscle mass

// Preparation

Reconstitution & Storage

No reconstitution needed — orforglipron is taken as a daily oral tablet. No fasting requirements (unlike oral semaglutide/Rybelsus). Can be taken with or without food.

Storage: Room temperature. No refrigeration required. Stable at standard storage conditions.

Ready to source LY-343794?

Compare prices across verified vendors. Find the best purity at the lowest price.

Compare Vendors →
// Safety Profile

Side Effects & Safety

Potential Side Effects

  • ! Nausea (dose-dependent, most common during titration)
  • ! Vomiting
  • ! Diarrhea
  • ! Constipation
  • ! Decreased appetite
  • ! Abdominal pain
  • ! Headache
  • ! Similar GI profile to injectable GLP-1 agonists

Contraindications

  • ⚠ Personal or family history of medullary thyroid carcinoma
  • ⚠ MEN 2 syndrome
  • ⚠ Pregnancy or breastfeeding
  • ⚠ History of pancreatitis
  • ⚠ Severe GI disease

Legal & Regulatory Status

Investigational — not yet FDA-approved. Currently in Phase 3 clinical trials (ACHIEVE program) by Eli Lilly. Not yet available from research vendors. Expected FDA submission in 2025-2026.

// Research

Published Research

// Where to Buy

Top Vendors for LY-343794

Ranked by our review scores. All vendors are independently tested.

B+
Read Review Visit Vendor →
B+
Read Review Visit Vendor →
B+
Read Review Visit Vendor →
// Related Compounds

Other GLP-1 Agonist Guides

Thymosin Alpha 1

A thymic peptide approved in 35+ countries that restores and enhances adaptive immunity — T-cell maturation, antiviral defense,…

Read Guide →

VIP

A master regulatory neuropeptide with broad anti-inflammatory, vasodilatory, and neuroprotective effects — critical in mold illness (CIRS) treatment…

Read Guide →

LL-37

The only human cathelicidin — a broad-spectrum antimicrobial peptide that kills pathogens, modulates inflammation, and promotes wound healing…

Read Guide →

Stay informed on LY-343794.

New research, dosage updates, and vendor deals. Straight to your inbox.

Free forever. No spam. Unsubscribe anytime.

This content is for informational and educational purposes only. LY-343794 is sold for research purposes. Never Natty does not condone or encourage the use of any substance in violation of any laws. Consult a healthcare professional before using any compound discussed on this site.